Two new models (Model 1: using fat-free mass and age information; Model 2: using fat-free mass, age and blood group information) were developed in order to expand the previous Eloctate models along the age continuum.
We are pleased to announce some added features to WAPPS-Hemo with the latest update.
Version 5.2 of WAPPS-Hemo introduces a large set of minor incremental updates, many on the back-end, to make our human validation more efficient, many in the connectivity to external software and applications, and many to the look and general functionalities.
For WAPPS-Hemo users located in Europe, McMaster is excited to announce the launch of McMaster PopPK. If you see value in using a CE-marked platform, then McMaster PopPK is now available for you. This new CE-marked platform provides individual pharmacokinetic parameters based on the trusted WAPPS-Hemo engine. McMaster PopPK is CE-marked as an in vitro diagnostic device class I in accordance with the EU IVD Directive. McMaster PopPK supports myWAPPS and florioTM to display estimated factor levels via patient smartphone apps.
WAPPS-Hemo is pleased to announce the launch of two new population pharmacokinetic (PK) models for ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Domain Truncated), PEGylated) that use the one-stage and chromogenic assays.
At WAPPS-News we post the latest updates and changes to the WAPPS-Hemo program. Check back with us regularly. Contact us if you have any questions.
The WAPPS-HEMO Team
If you have any WAPPS-Hemo related research or news items you would like to share, please contact us
© 2020 Copyright WAPPS-Hemo